Literature DB >> 15905614

Evaluation of tumour vascularisation in two rat sarcoma models for studying isolated lung perfusion. Injection route determines the origin of tumour vessels.

Youmin Pan1, T Krueger, Nam Tran, Hua Yan, H-B Ris, T A McKee.   

Abstract

Isolated cytostatic lung perfusion (ILP) is an attractive technique allowing delivery of a high-dose of cytostatic agents to the lungs while limiting systemic toxicity. In developing a rat model of ILP, we have analysed the effect of the route of tumour cell injection on the source of tumour vessels. Pulmonary sarcomas were established by injecting a sarcoma cell suspension either by the intravenous (i.v.) route or directly into the lung parenchyma. Ink perfusion through either pulmonary artery (PA) or bronchial arteries (BA) was performed and the characteristics of the tumour deposits defined. i.v. and direct injection methods induced pulmonary sarcoma nodules, with similar histological features. The intraparenchymal injection of tumour cells resulted in more reliable and reproducible tumour growth and was associated with a longer survival of the animals. i.v. injected tumours developed a PA-derived vascular tree whereas directly injected tumours developed a BA-derived vasculature. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2005        PMID: 15905614     DOI: 10.1159/000084539

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  2 in total

1.  Establishment of a large animal model for research on transbronchial arterial intervention for lung cancer.

Authors:  Zhichao Sun; Xiao An; Hongchao Liu; Weihua Dong; Xiangsheng Xiao
Journal:  Diagn Interv Radiol       Date:  2021-07       Impact factor: 2.630

2.  Transpulmonary chemoembolization (TPCE) as a treatment for unresectable lung metastases.

Authors:  Thomas J Vogl; Thomas Lehnert; Stephan Zangos; Katrin Eichler; Renate Hammerstingl; Huedayi Korkusuz; Sebastian Lindemayr
Journal:  Eur Radiol       Date:  2008-06-14       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.